+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Evaluation of gamma interferon release assays using Mycobacterium tuberculosis antigens for diagnosis of latent and active tuberculosis in Mycobacterium bovis BCG-vaccinated populations



Evaluation of gamma interferon release assays using Mycobacterium tuberculosis antigens for diagnosis of latent and active tuberculosis in Mycobacterium bovis BCG-vaccinated populations



Clinical and Vaccine Immunology 17(12): 1985-1990



T-cell-based gamma interferon (IFN-γ) release assays (IGRAs) using Mycobacterium tuberculosis-specific antigens have shown higher sensitivity and specificity than the routine tuberculin skin test (TST). However, the effects of Mycobacterium bovis BCG vaccination and anti-tuberculosis (TB) treatment on dynamic T-cell responses to M. tuberculosis-specific antigens in active TB cases have rarely been investigated in regions where TB is endemic. Eighty-nine patients with active pulmonary TB (ATB) and 57 healthy controls (HC) from China were recruited and tested by sputum smear and culture, TSTs, and IGRAs with M. tuberculosis-specific antigens ESAT-6 and CFP-10 (T-SPOT.TB) as well as purified protein derivative (PPD) stimulation. All 146 participants were screened by the T-SPOT.TB assay at recruitment. T-SPOT.TB-positive rates in ATB and HC groups were 87.6% (78/89) and 21.1% (12/57), respectively. Of 38 ATB patients who were both TST and T-SPOT.TB tested, the positive rates were 73.7% (28/38) and 94.7% (36/38), respectively (P = 0.0215), and those in the HC group were 62.3% (33/53) and 18.9% (10/53), respectively (P < 0.0001). The T-SPOT.TB-positive rates declined during TB treatment and were 94.4% (51/54), 86.4% (19/22), and 61.5% (8/13) for ATB patients receiving 0- to 1-month, 1- to 3-month, and 3- to 6-month anti-TB treatment, respectively. The IGRA is a most promising test for both active TB and latent TB infection (LTBI) diagnosis due to the improvement of its specificity and convenience, especially in the Mycobacterium bovis BCG-vaccinated population. Furthermore, the T-SPOT.TB assay using ESAT-6 and CFP-10 in ATB patients during anti-TB treatment could serve as a potential predictor of therapeutic efficacy.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 053072351

Download citation: RISBibTeXText

PMID: 20943878

DOI: 10.1128/cvi.00294-10


Related references

Comparison of T-cell interferon-gamma release assays for Mycobacterium tuberculosis-specific antigens in patients with active and latent tuberculosis. Lung 188(4): 283-287, 2010

Identification and evaluation of new Mycobacterium bovis antigens in the in vitro interferon gamma release assay for bovine tuberculosis diagnosis. Tuberculosis 95(6): 795-801, 2015

Diagnosis of Latent Mycobacterium tuberculosis Infection in the Era of Interferon Gamma Release Assays. Clinical Microbiology Newsletter 40(17): 139-144, 2018

Quantitative T-cell interferon-gamma responses to Mycobacterium tuberculosis-specific antigens in active and latent tuberculosis. European Journal of Clinical Microbiology and Infectious Diseases 28(6): 667-670, 2009

Latent Mycobacterium tuberculosis Infection and Interferon-Gamma Release Assays. Microbiology Spectrum 4(5):, 2016

Evaluation of T-cell interferon-gamma-release assays for the diagnosis of latent and active tuberculosis. Deutsche Medizinische Wochenschrift 133(8): 354-357, 2008

Commercial interferon gamma release assays compared to the tuberculin skin test for diagnosis of latent Mycobacterium tuberculosis infection in childhood contacts in the Gambia. Pediatric Infectious Disease Journal 29(5): 439-443, 2010

In vitro interferon gamma production in mice vaccinated with 'Mycobacterium habana' against Mycobacterium tuberculosis antigens. Revista Cubana de Medicina Tropical 64(3): 279-289, 2013

Distinguishing Latent from Active Mycobacterium tuberculosis Infection Using Elispot Assays: Looking Beyond Interferon-gamma. Cells 1(2): 89-99, 2012

Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection. European Respiratory Journal 38(5): 1237-8; Author's Reply 1238-9, 2011

Interferon- release assays for the diagnosis of latent Mycobacterium tuberculosis infection. European Respiratory Journal 38(5): 1238-1239, 2011

Interferon Gamma Release Assay in a 12-month-old BCG-Vaccinated Infant with Latent Tuberculosis Infection and Isolated Mycobacterium fortuitum. Laboratory Medicine 41(11): 662-664, 2010

Evaluation of the performance of two tuberculosis interferon gamma release assays (IGRA-ELISA and T-SPOT.TB) for diagnosing Mycobacterium tuberculosis infection. Clinica Chimica Acta; International Journal of Clinical Chemistry 479: 74-78, 2018

Evaluation of the performance of two tuberculosis interferon gamma release assays (IGRA-ELISA and T-SPOT.TB) for diagnosing Mycobacterium tuberculosis infection. Data in Brief 21: 2492-2495, 2018

Evaluation of the performance of two tuberculosis interferon gamma release assays (IGRA-ELISA and T-SPOT. TB ) for diagnosing Mycobacterium tuberculosis infection. Clinica Chimica Acta 479: 74-78, 2018